Nelsons launches Rescue Remedy Facebook contest
NORTH ANDOVER, Mass. — Nelsons on Tuesday announced a social media marketing initiative to help raise awareness around its stress-relieving product Rescue Remedy. Consumers who "like" Rescue Remedy" on Facebook as part of the "Want" To-Do List contest will be entered for a chance to win $2,500.
“We all have a want to do list running through our head, but time and money tend to make us put those things on the back-burner,” Rescue Remedy senior brand manager Katrina Eichenfeldt said. “We hope this campaign inspires people to be deliberate about carving out time for their own goals and to think about what they’ve always wanted to do.”
To enter, participants simply “Like” Rescue Remedy on Facebook and then follow the “Want” To-Do sweepstakes link to create their “Want” To-Do list. Once entered, participants will have the option of inviting their friends to enter as well. Each eligible friend who enters the sweepstakes gives the person who invited them an additional chance to win. Each participant also gets a Rescue Remedy coupon for entering.
Deadline for entries is Oct. 3, and the first prize winner of $2500 will be selected at random from all the respondents on Oct. 11.
Merrimack gets orphan drug designation for pancreatic cancer treatment
CAMBRIDGE, Mass. — The Food and Drug Administration has granted orphan drug designation to a chemotherapy drug made by Merrimack Pharmaceuticals for pancreatic cancer, the drug maker said Monday.
Merrimack announced that it received the designation for MM-398, described as a novel, stable, nanotherapeutic encapsulation of the chemotherapy drug irinotecan.
The FDA gives orphan drug designation to treatments for diseases that affect fewer than 200,000 people in the United States. Once approved, an orphan drug gets extended market exclusivity, regulatory fee reductions and support for research and development initiatives.
FDA gives new approval to Novartis MS drug
EAST HANOVER, N.J. — The Food and Drug Administration has approved a new use for a drug made by Novartis for treating multiple sclerosis, the Swiss drug maker’s U.S. subsidiary said Monday.
Novartis Pharmaceuticals announced the FDA’s approval of Gilenya (fingolimod) for the reduction of T1 gadolinium-enhancing lesions, areas of inflammation in the central nervous system that mark disease activity in people with MS.
"Neurologists commonly use gadolinium contrast MRI activity to assess for active inflammation in people living with MS," MS Center for Innovations in Care at the Missouri Baptist Medical Center director Barry Singer said. "These data show that treatment with Gilenya helped to significantly reduce contrast MRI activity in people with relapsing-remitting MS."